Minoxidil topique 5 % face à Spironolactone topique 1 % (gel)
1 essai les comparent directement, sur les mêmes patients. Voir Minoxidil topique 5 % · Voir Spironolactone topique 1 % (gel)
Le minoxidil topique 5 % et le gel de spironolactone 1 % font jeu égal dans le seul essai qui les compare, chez des adultes des deux sexes atteints d'alopécie androgénétique (Abdel-Raouf 2021). À un an, les cheveux repoussent chez 90 % des patients sous minoxidil (18 sur 20) et 80 % sous spironolactone (16 sur 20), un écart qui peut être dû au hasard. L'essai, de 60 participants, est de fiabilité limitée.
Abdel-Raouf 2021
Essai randomisé, risque de biais élevé. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study.
| Critère | Minoxidil topique 5 % | Spironolactone topique 1 % (gel) | Écart |
|---|---|---|---|
| Taux de repousse clinique | 90 % (18 sur 20)Voir la citationof AGA. The average time of hair loss in patients, were 26.36 ± 21.9 months. In group I treated with topical minoxidil gel 5%, clinical response were in 90% of the patients, four of them have excellent response, six have good response , two have fair response and six have poor response. In group II treated with topical spironolactone gel 1%, clinical improvement were in 80% of the patients, five of them have excellent response, four have good response, and seven patients have poor response. In group III treated with combined topical spironolactone 1% and minoxidil 5% gel, clinical improvement were in 100% of the patients, eight of them have excellent response, ten have good response, and two patients have fair response.. In comparison between group I and group II, there was insignificant difference between them (p= 0.516) while there was a significant difference between group I and group III, group II and group III (p= 0.035, p= 0.003 respectively) (Figs. 1). Abdel-Raouf H, Aly UF, Medhat W et al.. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study.. Dermatol Ther 2021, DOI 10.1111/dth.14678. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | 80 % (16 sur 20)Voir la citationof AGA. The average time of hair loss in patients, were 26.36 ± 21.9 months. In group I treated with topical minoxidil gel 5%, clinical response were in 90% of the patients, four of them have excellent response, six have good response , two have fair response and six have poor response. In group II treated with topical spironolactone gel 1%, clinical improvement were in 80% of the patients, five of them have excellent response, four have good response, and seven patients have poor response. In group III treated with combined topical spironolactone 1% and minoxidil 5% gel, clinical improvement were in 100% of the patients, eight of them have excellent response, ten have good response, and two patients have fair response.. In comparison between group I and group II, there was insignificant difference between them (p= 0.516) while there was a significant difference between group I and group III, group II and group III (p= 0.035, p= 0.003 respectively) (Figs. 1). Abdel-Raouf H, Aly UF, Medhat W et al.. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study.. Dermatol Ther 2021, DOI 10.1111/dth.14678. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | Peut être dû au hasard |